Oppenheimer Initiates Coverage On Xeris Biopharma Holdings with Outperform Rating, Announces Price Target of $5
Portfolio Pulse from Benzinga Newsdesk
Oppenheimer analyst Leland Gershell initiates coverage on Xeris Biopharma Holdings (NASDAQ:XERS) with an Outperform rating and a price target of $5.

March 28, 2024 | 10:51 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oppenheimer initiated coverage on Xeris Biopharma Holdings with an Outperform rating and a price target of $5.
The initiation of coverage by a reputable analyst with an Outperform rating and a specific price target usually indicates a positive outlook on the stock, suggesting potential upside. This can lead to increased investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100